The role of the immune response to oncolytic Herpes simplex viral (oHSV) therapy for glioblastoma is controversial because it might enhance or inhibit efficacy. We found that within hours of oHSV infection of glioblastomas in mice, activated natural killer (NK) cells are recruited to the site of infection. This response substantially diminished the efficacy of glioblastoma virotherapy. oHSV-activated NK cells coordinated macrophage and microglia activation within tumors. In vitro, human NK cells preferentially lysed oHSV-infected human glioblastoma cell lines. This enhanced killing depended on the NK cell natural cytotoxicity receptors (NCRs) NKp30 and NKp46, whose ligands are upregulated in oHSV-infected glioblastoma cells. We found that HSV titers and oHSV efficacy are increased in Ncr1 -/-mice and a Ncr1 -/-NK cell adoptive transfer model of glioma, respectively. These results demonstrate that glioblastoma virotherapy is limited partially by an antiviral NK cell response involving specific NCRs, uncovering new potential targets to enhance cancer virotherapy. 
The current standard of therapy for glioblastoma is palliative 1 . Attempts to improve survival involve various new approaches, including oncolytic virotherapy 2 . In virotherapy, naturally occurring or genetically engineered viruses selectively replicate in and lyse tumor cells while engendering an immune response to both virally infected and uninfected tumors. One such virus is oHSV, which is genetically modified to replicate in and lyse tumor cells through multiple rounds of viral replication 2 . To date, oHSV injected into human glioblastomas has been well tolerated, but efforts to demonstrate efficacy in early phase trials have been disappointing 3 . We have hypothesized that the host immune response to oHSV therapy for glioblastoma is a barrier to achieving clinical success 4 . This hypothesis is based on mouse and rat studies in which transient depletion of phagocytic macrophage populations or pharmacologic suppression of immunity improved the effect of oHSV [5] [6] [7] . However, the hypothesis that innate immunity is deleterious to virotherapy [5] [6] [7] [8] [9] [10] [11] runs counter to the argument that immune responses are beneficial to antitumor efficacy. In fact, the host immune response after oHSV administration in vivo has been shown to provoke an antitumor immune response against oHSV-infected cells and uninfected bystander tumor cells [12] [13] [14] [15] . Resolution of these apparently discordant views 16, 17 is important, as one would attempt to either evade or increase immunity to improve efficacy.
In this context, NK cells are the perfect foe or friend of virotherapy. NK cells are rapidly recruited to the site of viral infection and mediate viral clearance, thus making them a foe 11 . However, they also possess tumor-clearing properties whereby stimulating NK cell infiltration by oHSV could facilitate antitumor efficacy [18] [19] [20] [21] [22] . In the context of oHSV therapy, the antiviral compared to the antitumor role of NK cells has not been defined. The mechanisms by which NK cells eradicate virally infected cells are currently under intense investigation 23 . Human NK cells express a variety of receptors, including the NCRs NKp30, NKp44 and NKp46 that mediate NK cell cytotoxic functions. However, the key receptor-ligand interactions that coordinate the NK cell cytotoxic functions are not known.
In this report, we show that oHSV infection of experimental glioblastoma is characterized by rapid recruitment to the brain of NK cells with an activated phenotype. This response does not facilitate antitumor effects; rather, it leads to premature viral clearance and limits oHSV anticancer efficacy. In vitro, NK cell-mediated killing was primarily dependent on NKp30 and NKp46, which recognize ligands upregulated in oHSV-infected human glioblastoma cell lines. These findings were supported by studies in mice lacking NKp46 (Ncr1 −/− mice) that showed the antiviral role of NKp46. These results demonstrate that the initial in vivo antiviral NK cell response to oHSV is detrimental in mouse models and suggests NKp30 and NKp46 as potential clinical targets to improve virotherapy.
RESULTS oHSV induces rapid NK cell recruitment and activation
We first investigated whether there was an increase in NK cell infiltration after administering the oHSV, rQNestin34.5 (ref. 24 ) into orthotopic human glioblastoma (U87dEGFR) xenografts and syngeneic mouse glioblastoma (KR158dEGFR). rQNestin34.5 selectively replicates based on the mutational insertion of GFP into the Herpes simplex virus 1 (HSV-1) ICP6 locus, providing selectivity for p16 −/− cells 25 , and on transcriptional regulation of the HSV-1 gene product ICP34.5 by the nestin promoter, providing selectivity for nestin-positive glioblastomas 24 . We found a significant increase in the total number of NK cells 2 h after oHSV infection (Fig. 1a) . Compared to mice treated with HBSS or heat-inactivated oHSV, NK cell recruitment required viral replication and increased for up to 72 h in mice treated with rQNestin34.5 (Fig. 1b,c and Supplementary  Fig. 1a-c) . We confirmed the presence of NK cells in the brains of rQNestin34.5-treated mice that were perfused before mononuclear cell isolation (Supplementary Fig. 1b) . NK cell recruitment also occurred after intracranial administration of wild-type (WT) HSV-1 (Supplementary Fig. 1b) . These results thus showed that active oHSV replication elicited a rapid elevation in the number of NK cells into xenograft and syngeneic mouse glioblastomas. (b) FACS quantification of the total number of NK cells in tumor-bearing hemispheres at 6, 24 or 72 h after inoculation with rQNestin34.5, heat-inactivated oHSV or vehicle in athymic mice bearing U87dEGFR tumors (n = 4-5 mice per group). (c) NK cell quantification in the brains of mice after rQNestin34.5 injection into intracranial U87dEGFR xenografts or WT HSV-1 in the brains of mice with no tumor, in tumor-bearing mice treated with vehicle or in untreated tumor-bearing mice (n = 3-5 mice per group). *P < 0.05, ***P < 0.001; Student's t test was used to calculate statistical significance in a and c, and two-way analysis of variance (ANOVA) and pairwise comparisons were used in b. Error bars, s.d. We next characterized the activation status of recruited NK cells by evaluating the expression of 11 different surface antigens. oHSV administration induced a unique phenotype in NK cells recruited to the site of infection ( Fig. 2a and Supplementary Table 1a) that was not present in peripheral NK cells (Supplementary Fig. 2 ). The expression levels of CD27 and CD11b denote three distinct NK cell functional subpopulations 26 : immature CD11b low CD27 high , cytotoxic CD11b high CD27 high and senescent CD11b high CD27 low . Although NK cells recruited to tumors in vehicle-treated mice were mostly CD11b high CD27 low , oHSV administration resulted in recruitment of CD11b high CD27 high or CD11b low CD27 high NK cells (Fig. 2b,c and Supplementary Table 1b) . oHSV infection induced a threefold and a sevenfold increase in the expression of the degranulation marker CD107a in CD11b high CD27 low and CD11b high CD27 high NK cells, respectively (Fig. 2d) . Therefore, oHSV enhances the recruitment of distinct NK cell subsets expressing cytotoxic NK cell markers.
Macrophage activation occurs in a NK cell-dependent manner Because NK cells are thought to coordinate macrophage activation 27 , we examined whether recruited NK cells orchestrate this response in the context of virotherapy. oHSV treatment reduced the percentage of CD115 + CD45 low CD11b + cells (microglia) and concomitantly increased both CD115 + CD45 high CD11b + mononuclear (macrophages) and CD115 + CD45 high CD11b low lymphocyte populations compared to HBSS treatment (Fig. 3a) . We further found that CD115 + CD45 high CD11b + cells showed markedly enhanced expression of macrophage activation markers. However, NK cell depletion 28 attenuated this response ( Fig. 3b and Supplementary Fig. 3a) . To assess the retention of macrophages and microglia after NK cell depletion, we gated on CD115, a marker for monocyte-derived cells 29 . We then quantified the total numbers of CD115 + CD45 low CD11b + and CD115 + CD45 high CD11b + cells. Notably, NK cell depletion with antibodies to either asialo-GM1 or TMβ1 before oHSV inoculation did not alter the total number of CD115 + CD45 low CD11b + and CD115 + CD45 high CD11b + cells in the tumor compared to mockdepleted mice (Fig. 3c) . We further confirmed an equal number of intracranial macrophages and microglia after NK cell depletion by staining for CD45 + F4/80 + Gr1 + cells (Supplementary Fig. 3b ). Therefore, NK cell depletion attenuated the expression of macrophage and microglia activation markers, rather than reducing their cell numbers, in tumors in response to oHSV infection. We then analyzed markers of macrophage and microglia activation. oHSV infection of glioblastoma in vivo significantly increased the gene expression and protein production of nitric oxide synthase 2 (Nos2) and tumor necrosis factor (Tnf), whereas NK cell depletion attenuated this response ( Fig. 3d-h ). By adoptively transferring WT NK cells into Ifng −/− mice, we demonstrated that Nos2 induction depended on NK cell-derived Ifng gene expression (Fig. 3f,g and Supplementary  Fig. 3c ). In addition, expression of the genes encoding the interferon γ (Ifng)-inducible chemokines (IIC) Cxcl9, Cxcl10 and Cxcl11 significantly increased after oHSV therapy (Fig. 3i,j) . This increase did not occur if NK cells were depleted or in Ifng −/− mice (Fig. 3i,j) . Consistent with the notion that IIC expression is associated with macrophage and microglia activation but is not necessarily derived from these cells, IIC expression was not significantly altered within these cell populations after NK cell depletion (Supplementary Fig. 3d) . Together, these results show that virotherapy results in NK cell-mediated macrophage and microglia activation, which has been reported to correlate, in general, with both anticancer and antiviral properties 30 .
Depletion of NK cells in vivo enhances efficacy of oHSV
The observed NK-cell and macrophage activation could potentially hinder virotherapy by eliminating oHSVs. After confirming our ability to deplete NK cells in glioblastoma-bearing mice ( Supplementary  Fig. 4a-c) , we found that NK cell depletion led to significantly elevated titers of rQNestin34.5 compared to NK-replete mice (Fig. 4a) . Notably, NK cell depletion (by antibodies to either asialo-GM1 or TMβ1) significantly increased the survival of mice bearing orthotopic glioblastoma xenografts treated with oHSV (Fig. 4b) . We recapitulated these findings by depleting NK cells with either antibodies to TMβ1 or NK1.1 in a mouse syngeneic model 31 (Fig. 4c,d) .
To assess the inflammatory response induced by oHSV, we used a mouse inflammatory gene expression array. We found significantly induced gene expression in 30 out of 84 genes in tumors treated with oHSV. This included over 100-fold induction of the expression of Cxcl9, Cxcl10, Cxcl11, Ccl2 and Ccl7. NK cell depletion reduced the induction of all 30 genes by oHSV (Fig. 4e,f and Supplementary Table 2 ). These results indicate that NK cell recruitment after oHSV infection of gliomas leads to a significant increase in inflammatory gene expression that can be reduced almost back to baseline with NK cell depletion.
NKp30 and NKp46 are mediators of oHSV viral clearance As interleukin-15 (IL-15) was upregulated by oHSV in tumors (Supplementary Fig. 5a ), we assessed the cytotoxicity of IL-15-activated human NK cells. IL-15-activated human NK cells showed enhanced toxicity against oHSV-infected human glioblastoma cells compared to uninfected glioblastoma cells (Fig. 5a) . Unstimulated NK cells were also more cytotoxic against oHSV-infected compared to uninfected glioblastoma cells, albeit to a reduced degree than the cytotoxicity shown by IL-15-activated NK cells against infected tumor cells (Supplementary Fig. 5b ). IL-15-activated mouse NK cells also preferentially killed oHSV-infected glioblastoma cells (Fig. 5b) . Notably, this antiviral response was unique to NK cells, as cytotoxic T lymphocytes (CTLs) from human donors were unable to recapitulate this cytotoxicity profile (Supplementary Fig. 5c ). Collectively, activated and unstimulated NK cells were more cytotoxic against oHSV-infected than uninfected glioblastoma cells.
To further explore the mechanism of enhanced cytotoxicity, we found that oHSV infection led to cell contact-dependent and perforin-dependent 32, 33 killing (Supplementary Fig. 6a ), minor alterations in human leukocyte antigen (HLA)-ABC staining (Supplementary Fig. 6b ) and no change in the expression of the NK cell-activating receptors DNAM-1 and NKG2D (Supplementary Fig. 6c) . Blockade of NKG2D inhibited killing of one of four glioblastoma cell lines, but this effect was not significant when all glioblastoma cell lines were analyzed collectively (P = 0.34) (Supplementary Fig. 6a ). DNAM-1 blockade achieved moderate inhibition of cell killing in both oHSV-(P = 0.03) and mock-infected cells (P = 0.01) ( Supplementary  Fig. 6d) . Therefore, it seemed that NK cell cytotoxicity was only partially dependent on canonical NK cell receptor recognition of oHSV-infected tumor cell lines.
We thus determined whether NCRs mediated the lysis of oHSVinfected glioblastoma cells 34, 35 . We significantly inhibited NK cellmediated in vitro killing using blocking antibodies to either NKp30 (P = 0.003) or NKp46 (P = 0.02) (Fig. 6a) . In a mouse in vitro model, NKp46 (the only NCR in mice) mediated NK cell killing of oHSVinfected glioblastoma cells (Supplementary Fig. 6e) . Moreover, we showed enhanced NCR ligand expression in oHSV-infected glioblastoma cells in vitro, measured by using the NCR fusion protein NKp30-immunoglobulin (Fig. 6b) . GFP is used to detect rQNestin34.5 infection, and the highly infected (GFP high ) cell population also had maximum NKp30 ligand staining compared to uninfected cells (Fig. 6c) . Similarly, there was enhanced NCR ligand expression in oHSV-infected glioblastoma cells in vitro, assayed by using the NCR fusion protein NKp46-immunoglobulin (Fig. 6d) , and the highly infected (GFP high ) cell population also had maximum NKp46 ligand staining compared to uninfected cells (Fig. 6e) . Notably, the upregulated NCR ligands were not the recently described NKp30 ligand B7-H6 (ref. 36 and data not shown).
We also investigated whether NCR ligands were upregulated after various modes of cellular stress, including exposure to temozolomide (TMZ), which is the chemotherapeutic agent used in the treatment of glioblastoma. Although radiation or hypoxia induced moderate expression of NKp30 ligand but not the NKp46 ligand, TMZ induced the expression of both NKp30 and the NKp46 ligand to the same levels as did oHSV (Fig. 6f,g) . Therefore, NK cell-mediated cytotoxicity of oHSV-treated glioblastoma cells is coordinated primarily through the NK cell receptors NKp30 and NKp46, which recognize cognate ligands on tumor cells that are upregulated by oHSV or TMZ.
To assess the role of NKp46 in viral clearance in vivo, we quantified WT HSV-1 replication after intracerebral inoculation in the brains of Ncr1 −/− and WT mice. Compared to those in WT mice, WT HSV-1 titers were significantly enhanced in Ncr1 −/− mice (Fig. 6h) . We next investigated whether NKp46-deficient NK cells would lead to improved survival in our virotherapy tumor model. We adoptively transferred enriched NK cells from WT or Ncr1 −/− mice into sublethally irradiated severe combined immunodeficient (SCID)-γc null mice (lacking host B, T and NK cells) and then performed intracranial tumor implantation. We found that oHSV treatment led to prolonged survival in glioma-bearing SCID mice transplanted with NKp46-deficient NK cells compared to glioma-bearing SCID mice transplanted with WT NK cells (Fig. 6i) , thus showing the importance of NKp46 in the ability of NK cells to impede the antitumor action of oHSV.
DISCUSSION
Here we explored the response of innate immunity to oHSV therapy of glioblastoma. We discovered a rapid NK cell response to tumor infection with oHSV. This in vivo antiviral NK cell response depends on specific cytotoxic NK cell subsets in the brain that also coordinate macrophage activation and leads to rapid killing of oHSV-infected glioblastoma cells. NK cell depletion improves the survival of glioblastoma-bearing mice treated with oHSV. We have discovered that oHSV-infected human glioblastomas upregulate ligands for the NK cell natural cytotoxicity receptors NKp30 and NKp46 in vitro. Recognition of these ligands is crucial for NK cell-mediated cytotoxicity directed against oHSV-infected cells and viral clearance in vivo. Collectively, we demonstrate that the rapid NK cell response to oHSV therapy cooperates with other innate immune cells to reduce, rather than enhance, the efficacy of oHSV treatment through NKp30 and NKp46. We argue that these findings, combined with clinical reports of patients with deficiencies in NK cell function being susceptible to HSV-1 encephalitis 37 , suggest that NK cells represent a substantial barrier to oHSV therapy of glioblastoma. The role of NK cells in mediating the efficacy of virotherapy is controversial. Most studies show enhanced oHSV efficacy by eliciting an NK cell-mediated antitumor response [18] [19] [20] [21] . Only one previous study described the antiviral properties of NK cells as being detrimental to vesicular stomatitis virus therapy for hepatocellular carcinoma 38 . Our evidence shows that NK cells rapidly responding to oHSV infection of glioblastoma constitute a barrier to therapeutic efficacy. First, there is a decline in viral titers within days of oHSV administration [5] [6] [7] [8] . Second, in preclinical studies, the clearance of oHSV approaches 80%, corresponding to rapid peripheral macrophage recruitment into the site of viral infection 5, 7 , suggesting a mechanism of oHSV clearance. 
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These findings were validated through a study demonstrating that macrophage depletion enhanced the efficacy of oHSV therapy in glioblastoma 5 . Third, a recent clinical trial of oHSV for glioblastoma noted prominent inflammatory infiltration within the tumor, correlating with reduced oHSV replication 3 . Fourth, mathematical modeling has previously shown that the timing of the antiviral innate immune response is detrimental to oHSV therapy 9 . Collectively, this evidence strongly suggests that an initial innate immunity to oHSV therapy is detrimental to anticancer efficacy. However, other studies have shown that immune responses to vesicular stomatitis virus virotherapy for metastatic non-central nervous system tumors are highly desirable 20, 39, 40 . Therefore, the effect of immunity on the efficacy of virotherapy may require a balance between virus replication and antitumor responses that may differ on the basis of the oncolytic virus and tumor.
For the first time, to our knowledge, we show that mouse NK cells recruited to an oHSV-infected brain tumor upregulate markers of an activated phenotype. Knowing that NK cells produce substantial amounts of Ifng and oHSV replication is enhanced in both Ifng-and macrophage-depleted mice 5,7 led us to hypothesize that NK cells mediate oHSV-induced macrophage and microglia activation 41 . We demonstrated that this activation, occurring after oHSV administration, is NK-cell and Ifng dependent. Our results argue that the reduction of macrophage and microglia activation markers, including Nos2, Tnf and IIC, in oHSV-infected tumors was probably caused by the loss of NK cell-mediated activation (in the setting of NK cell depletion with NK antibodies) rather than by the loss of macrophage and microglia cell numbers. Notably, oHSV infection led to a robust NK cell-dependent and Ifng-dependent induction of Cxcl9, Cxcl10 and Cxcl11 expression. These chemokines are associated with macrophage activation and herpes encephalitis 41 . Future clinical studies should assess whether the recruitment of IFNG-producing CD3 − CD56 bright CD94 bright human NK cells 42 is associated with both oHSV inoculation and the activation of macrophages and microglia. Similarly, the CD3 − CD56 dim CD94 dim NK cell subset 42 , which is associated with cell-mediated killing, may translate into preferential killing of virally infected glioblastoma cells before efficacious oncolysis has occurred. Future clinical trials should clarify the NK cell subsets by examining CD56 and CD94 expression 42 , along with their associated functional properties.
We also assessed the effect of NK cell depletion in a fully immunocompetent mouse model. After screening several mouse glioblastomas, the KR158dEGFR glioblastoma line showed oHSV replication and cytotoxicity in vitro approximating that of human glioblastomas (data not shown). However, KR158dEGFR is syngeneic to C57BL/6 mice, a strain that is notoriously impervious to HSV-1 infection 43 . Because of minimal in vivo viral replication in this model (data not shown), we instead used the mouse 4C8 model 31 . Although oHSV replicates about 1.5 log times less in 4C8 cells than in human glioma cells (data not shown), the syngeneic B6D2F1/J mouse strain is more sensitive to HSV-1 infection than the C57BL/6 strain 15 . Yet, even in this model, we found significant survival from syngeneic gliomas with oHSV treatment only in the absence of NK cells, further underscoring the importance of NK cells in limiting glioma virotherapy.
A common feature of glioblastoma is the endogenous expression of ligands for activating NK cell receptors 34, 35 . Recent studies have explored the role of HSV-1 infection in modulating the expression of NK cell-activating ligands. In human glioblastoma cell lines infected with oHSV, we observed upregulation of ligands for NKp46 and NKp30. Blockade of these two receptors significantly reduced NK cell cytotoxicity. Increases in tumor cell ligand expression occur with oHSV infection or treatment with TMZ but not with other methods of tumor killing. These data argue for a relatively specific increased recognition of the ligands for NKp30 and NKp46.
The identity of ligands for NCRs is a field of intense investigation 44 , with influenza hemagglutinin having been identified as an activating ligand for NKp46 and NKp44 (ref. 45) . NKp30 is involved in viral eradication by binding to an unknown ligand on immature dendritic cells 46 and in viral evasion through its recognition of the human cytomegalovirus tegument protein pp65 (refs. 47,48) . Additionally, NKp30 recognizes B7-H6 (ref. 36 ), a cell-surface protein that is associated with tumor formation, and Bat3 (ref. 49 ), a released cellular stress protein. Although NKp30 and NKp46 mediated NK cell lysis of oHSV-infected glioblastoma, B7-H6 did not seem to be involved. Moreover, cell-surface expression of the NKp30 and NKp46 ligands was similar after either oHSV infection or treatment with TMZ. These findings suggest that the ligands for NKp30 and NKp46 are of cellular rather than viral origin. Once the identities of the NKp30 and NKp46 ligands are uncovered, future work will investigate whether they can predict sensitivity to oncolysis for personalized treatment.
As NCR expression is differentially regulated to high (NCR bright ) or low levels (NCR dim ) of expression (ref. 50) , future clinical studies should examine the NCR phenotype after oHSV treatment and assess whether the expression of NCRs correlates with diminished viral replication. By clarifying the crucial receptor-ligand interactions that mediate human NK cell killing of oHSV-infected glioblastoma, we have uncovered a potential therapeutic target that, when blocked in vivo, could limit NK cell clearance of these infected cells in future clinical trials.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Cell culture. We used human glioblastoma cell lines (U87dEGFR, U251 and Gli36dEGFR), primary human glioblastoma cells enriched for stem cell-like properties (X12 (ref. 51) ), mouse glioblastoma cell lines (KR158dEGFR 52 and 4C8 (ref. 15) ) and African green monkey kidney (Vero) cells. We cultured cells in DMEM (Invitrogen) supplemented with 10% FBS, penicillin (100 U ml −1 ), and streptomycin (100 µg ml −1 ). We cultured human-and mouse-derived NK cells in RPMI-1640 (Invitrogen) supplemented with 10% FBS, penicillin (100 U ml −1 ), and streptomycin (100 µg ml −1 ). We cultured cells at 37 °C supplemented with 5% CO 2 .
Mouse studies. The Institutional Animal Care and Use Committee at Ohio State University approved all mouse experiments and care. We anesthetized athymic, C57BL/6 (Charles River Laboratories), B6.129S7-Ifng tm1Ts /J (Ifng −/− ), B6D2F1/J and nonobese diabetic (NOD)-SCID IL-2Rγ null (SCID-γc null ) 8-week-old female mice 53 Flow cytometric analysis. We isolated mononuclear cells from oHSV-infected brains using a previously described procedure 57 . For analysis of splenocytederived NK cell levels, we collected and homogenized tissues through a 70-µm strainer. We lysed erythrocytes using RBC Lysis Buffer (Biolegend). We treated cells, isolated from either the brain or the spleen, with Fc Block (BD). We then stained cells with mouse-specific immune cell surface markers for 30 min at 4 °C. We used mouse-specific antibodies to the following at a dilution Biotec) . For CD107a staining, we cultured mononuclear cells in 10% RPMI with monensin (eBioscience) for 4 h before cell-surface staining. For Tnf staining, we cultured mononuclear cells in 10% RPMI with Golgi-Plug (BD) for 4 h before intracellular staining. For staining of both Tnf and Nos2, we followed the initial cell-surface staining with Cytofix/Cytoperm (BD) and then with intracellular staining. A FACS Calibur (Becton Dickinson) was used for analysis. Viral yield assay. We measured titers of infectious virus particles recovered from virus-inoculated brains as follows. We inoculated athymic mice bearing 9-day-old U87dEGFR tumors intratumorally with 5 × 10 5 plaque-forming units of rQNestin34.5. C57BL/6 or Ncr1 −/− mice were intracranially inoculated with 10 4 plaque-forming units of WT HSV-1. Seventy-two hours later, we recovered the titers of infectious virus particles as described 5 .
Quantitative real-time RT-PCR. We isolated total RNA from tumor-bearing hemispheres using the RNeasy Lipid Tissue Midi kit (Qiagen) with quantitative realtime PCR performed as previously described using the SYBR Green PCR Master Mix and an ABI PRISM 7500 sequence detection system (Applied Biosystems) 8 . We used the following primers: 5′-GAACGGAGATCAAACCTGCCT-3′ and 5′-TGTAGTCTTCCTTGAACGACGA-3′ for Cxcl9; 5′-TGGAGGAACT GGCAAAAGGA-3′ and 5′-TGTTGCTGATGGCCTGATTG-3′ for Ifng; 5′-CAGCTGGGCTGTACAAACCTT-3′ and 5′-CATTGGAAGTGAAGCGTT TCG-3′ for Nos2; 5′-CATATGGAATCCAACTGGATAGATGTAAGATA-3′ and 5′-CATATGCTCGAGGGACGTGTTGATGAACAT-3′ for Il15; 5′-AAGCC TGTAGCCCACGTCGTA-3′ and 5′-GGCACCACTAGTTGGTTGTCTTTG-3′ for Tnf; 5′-TGAATCCGGAATCTAAGACCATCAA-3′ and 5′-AGGACTAG CCATCCACTGGGTAAAG-3′ for Cxcl10; 5′-GGCTGCGACAAAGTTGAAG TGA-3′ and 5′-TCCTGGCACAGAGTTCTTATTGGAG-3′ for Cxcl11; and 5′-AAATGGTGAAGGTCGGTGTG-3′ and 5′-TGAAGGGGTCGTTGATGG-3′ for the internal control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). We sorted brain leukocytes with antibodies to mouse CD45-APC and CD11b-PE using FACS (BD FACSAria). We isolated total RNA from 20,000 cells of each population with the RNeasy Micro Kit (Invitrogen) and analyzed them by quantitative real-time RT-PCR. To assess inflammatory gene expression, we used the Mouse Inflammatory Cytokines and Receptors RT 2 Profiler PCR Array (Super Array Bioscience Corporation) following the manufacturer's instructions.
NK cell isolation.
We enriched NK cells or CTLs from peripheral blood leukopacks of healthy donors (American Red Cross, Columbus, Ohio) using RosetteSep cocktail (StemCell Technologies) and either CD56 or CD8 magnetic bead sorting (Miltenyi Biotec). Isolation was performed after approval of a human subject protocol by the Institutional Review Board of the James Cancer Hospital at the Ohio State University (protocol number: 2009A0033; protocol name: Immunology of Cancer and Inflammation). Mouse NK cells were isolated from mouse splenocytes using positive selection bead sorting for DX5.
Cytotoxicity assay. We plated a panel of human glioblastoma cells overnight and infected them the next day with rQNestin34.5 (multiplicity of infection, 1.0) or mock infected them. Eight hours later, we added human NK cells or CTLs at different effector-to-target ratios in the presence of human IL-15 (for NK cells) or IL-2 (for CTLs) (Miltenyi Biotec). The coculture was allowed to proceed for 4 h at 37 °C. We assessed glioblastoma lysis with the Vybrant Cytotoxicity Assay Kit (Molecular Probes). For studies evaluating pharmacological inhibitors of cytolysis, we preincubated NK cells for 1 h with: EGTA/Mg 2+ (2 mM/4 mM) or chloroquine (100 µg ml −1 ). For NCR masking experiments, we preincubated NK cells for 1 h with the appropriate blocking antibody. We treated human NK cells with blocking antibodies (provided by A.M.) to the following at 10 µg ml −1 : DNAM-1 (F5), NKp30 (F252), NKp44 (KS38), NKp46 (KL247) and NKG2D (BAT221) 58 . Mouse NK cells were treated with blocking antibody to mouse NKp46 (29A1.4) at 10 µg ml −1 (ref. 59) (provided by E.V.). We then added NK cells to infected or mock-infected glioblastomas and cocultured them for 4 h at 37 °C.
Analysis of NK cell ligand expression. We used recombinant human NKp30-IgG or NKp46-IgG fusion proteins (R&D Systems) to investigate the expression of NK cell ligands on glioblastoma cells 8 h after oHSV infection or after treatment with TMZ (200 µM), 10 Gy radiation or hypoxia (1% O 2 and 5% CO 2 ). We stained for NK cell ligands by the addition of 10 µl of reconstituted IgG fusion proteins followed by incubation with APC-conjugated mouse antibody to human IgGfc (Jackson ImmunoResearch, 109-136-098) at a 1:100 dilution 35 . We also analyzed the expression of B7-H6 after oHSV infection of glioblastoma. Eight hours after infection, we also tested B7-H6 expression with 10 µg ml −1 of mouse antibody to human B7-H6 (gift from ZymoGenetics). We assessed cell-surface staining of oHSV-or mock-infected glioblastoma with humanspecific antibodies to the following at a dilution of 1:10: MICA/B-PE (159207), ULBP-1-PE (170818), ULBP-2-PE (165903) and CD155-PE (300907) (R&D); HLA-ABC-PE (W6/32) (eBioscience); and CD48-PE (BJ40) and CD112-PE (TX31) (Biolegend).
Statistical analyses. All statistical tests were two sided. We used ANOVA models or t tests to study group differences for all the continuous outcome variables. A χ 2 test was used to compare counts or proportions. We used log-rank tests to compare group effects on time-to-event variables. Total NK cells and percentages of NK cells were log transformed (natural log) to achieve normality. We used two-way ANOVA models to study the association between groups (U87dEGFR plus vehicle, U87dEGFR plus rQNestin34.5 and U87dEGFR plus heat-inactivated rQNestin34.5), time and the total number or percentage of NK cells. The interaction term treatment × time was also included in the models. The interaction term was significant in the model for Figure 1b and Supplementary  Figure 1a , and this is because of the larger slope or rate of increase in the total number and percentage of NK cells, respectively, across time observed in the U87dEGFR plus rQNestin34.5 treatment group. We performed pairwise comparisons when the group main effect was significant in the ANOVA model ( Fig. 1b and Supplementary Fig. 1a) . We used two-sample t tests to compare outcome variables between groups (Figs. 1c and 3b,d,e,g,i,j, Supplementary  Figs. 1c and 2b,c and Supplementary Tables 1a,b and 2a,b) . We used two-way ANOVA to compare the NK cell fold increase (natural log) across different phenotypes and different groups. The interaction term was included and found to be highly significant (Fig. 2c) . We compared the percentage of glioblastoma lysis using pairwise comparisons (chloroquine or EGTA/Mg 2+ compared to untreated) and found it to be significant (Supplementary Fig. 6a ). We used χ 2 tests (3 × 2 tables) to study the differences in cell type proportions between groups (treated or untreated) at each time point (6, 24 and 72 h).
